Depression and anxiety predict postsurgical pain in women with gynecologic cancer
Depression and anxiety, not just inflammation, predict pain intensity and interference with daily life among women recovering from gynecologic cancer surgery.
ASCO 2014 Annual Meeting
Ginger extract improves chemotherapy-induced nausea, vomiting
A ginger extract, 6-gingerol, improves chemotherapy-induced nausea and vomiting (CINV), according to findings from a phase 2 randomized trial presented at the 2014 Annual ASCO Meeting.
Patients’ symptom concerns before anticancer treatment predict symptom burdens
Patients who express pretreatment concern about treatment symptoms such as nausea and memory problems tend to suffer higher symptom burdens during and after anticancer treatment, suggests research.
Internal lymphedema underlies swallow dysfunction in head and neck cancer
Treatment-related dysphagia symptoms are likely caused by internal lymphedema among patients with head and neck cancer, according to research presented at the 2014 ASCO Annual Meeting.
Metastatic tumor sites predict OS in castration resistant prostate cancer
The site of metastatic tumors powerfully predicts overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC), confirms a meta-analysis presented at the 2014 American Society of Clinical Oncology Annual Meeting.
‘Excellent’ survival in biology-based pediatric neuroblastoma treatment reduction
Tumor biology-based therapy offers excellent outcomes among children with intermediate risk neuroblastoma, according to results from a prospective phase 3 reduction of therapy study.
Few Obese Patients with Gynecologic Cancers Counseled on Weight Loss
Obese patients with gynecologic cancer are rarely counseled on weight loss, even though they expect to be, and report that such discussions would not offend them, according to research.
Community Cancer Centers Program Participation Increases Rural Clinical Trial Enrollment
Expanding the National Cancer Institute (NCI) Community Cancer Centers Program within a rural community can increase the number of patients enrolled in clinical trials
Ridaforolimus + AKT Inhibitor Phase 1 Trial: Tolerable but Modest Efficacy for Breast Cancer
Combination ridaforolimus + MK-2206 AKT inhibitor therapy yielded modest early clinical efficacy results for patients with low-RAS advanced breast cancer and PTEN-deficient prostate cancer.
Shared Decision-making Ups Clinical Trial Participation, But Few Still Enroll
Fewer than 5% of adults with cancer enroll in clinical trials, despite such enrollment being critical to evaluate new therapies.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...